Moderate-to-severe cognitive impairment is associated with both recent and chronic alcohol misuse in people with HIV: The New Orleans alcohol use in HIV (NOAH) study.
| Title: | Moderate-to-severe cognitive impairment is associated with both recent and chronic alcohol misuse in people with HIV: The New Orleans alcohol use in HIV (NOAH) study. |
|---|---|
| Authors: | Fitzpatrick-Schmidt T; Comprehensive Alcohol-HIV/AIDS Research Center, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Department of Physiology, School of Medicine, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Alcohol & Drug Abuse Center of Excellence, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Oral E; Comprehensive Alcohol-HIV/AIDS Research Center, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Biostatistics, School of Public Health, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Welsh DA; Comprehensive Alcohol-HIV/AIDS Research Center, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Alcohol & Drug Abuse Center of Excellence, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Molina PE; Comprehensive Alcohol-HIV/AIDS Research Center, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Department of Physiology, School of Medicine, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Alcohol & Drug Abuse Center of Excellence, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Ferguson TF; Comprehensive Alcohol-HIV/AIDS Research Center, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Department of Physiology, School of Medicine, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Alcohol & Drug Abuse Center of Excellence, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Epidemiology, School of Public Health, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Edwards S; Comprehensive Alcohol-HIV/AIDS Research Center, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Department of Physiology, School of Medicine, LSU Health Sciences Center, New Orleans, Louisiana, USA.; Alcohol & Drug Abuse Center of Excellence, LSU Health Sciences Center, New Orleans, Louisiana, USA. |
| Source: | Alcohol, clinical & experimental research [Alcohol Clin Exp Res (Hoboken)] 2024 Jul; Vol. 48 (7), pp. 1405-1416. Date of Electronic Publication: 2024 Jun 02. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Wiley Periodicals Country of Publication: United States NLM ID: 9918609780906676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2993-7175 (Electronic) Linking ISSN: 29937175 NLM ISO Abbreviation: Alcohol Clin Exp Res (Hoboken) Subsets: MEDLINE; PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Hoboken, NJ : Wiley Periodicals, [2023]- |
| Abstract: | Background: Human immunodeficiency virus (HIV) profoundly impacts the nervous system, leading to neurological deficits including HIV-associated neurocognitive disorder (HAND). HAND represents the most common neurological comorbidity among people with HIV (PWH), and alcohol use may exacerbate cognitive deficits, especially in vulnerable populations. This study investigated relationships between alcohol use and cognition in an underserved cohort of PWH, on the hypothesis that alcohol misuse exacerbates cognitive deficits.; Methods: Data collected from participants (n = 259; 66.7% male; mean age 52 ± 10 years) enrolled in the New Orleans Alcohol Use in HIV (NOAH) study were utilized for cross-sectional analysis. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), and alcohol use was comprehensively measured using four metrics: the Alcohol Use Disorders Identification Test (AUDIT), 30-day timeline follow back (TLFB), lifetime drinking history, and phosphatidylethanol (PEth) levels.; Results: The average MoCA score among participants was 20.7 ± 4.5, with 86.5% demonstrating cognitive impairment (MoCA |
| References: | Subst Abus. 2018 Jan 2;39(1):116-123. (PMID: 29058572); Neurol Clin. 2010 Feb;28(1):253-75. (PMID: 19932385); Int J Geriatr Psychiatry. 2018 Feb;33(2):379-388. (PMID: 28731508); Alcohol Clin Exp Res. 2017 Oct;41(10):1745-1753. (PMID: 28792620); J Neurovirol. 2015 Aug;21(4):383-90. (PMID: 25678141); Alzheimers Res Ther. 2020 Apr 7;12(1):39. (PMID: 32264975); Neuropsychology. 2019 Sep;33(6):760-780. (PMID: 31448945); Alcohol Clin Exp Res. 2016 Nov;40(11):2435-2444. (PMID: 27658235); Alzheimer Dis Assoc Disord. 2018 Apr-Jun;32(2):120-124. (PMID: 29319601); J Psychosom Res. 2016 Jan;80:53-7. (PMID: 26721548); Addiction. 1993 Jun;88(6):791-804. (PMID: 8329970); Medicine (Baltimore). 2022 Oct 21;101(42):e31125. (PMID: 36281153); Alcohol Clin Exp Res. 2020 Jun;44(6):1261-1272. (PMID: 32441814); Alcohol Clin Exp Res. 2009 Oct;33(10):1815-24. (PMID: 19656122); Viruses. 2023 Jan 28;15(2):. (PMID: 36851592); J Clin Exp Neuropsychol. 2018 May;40(4):357-376. (PMID: 28689493); Nat Rev Neurol. 2016 Apr;12(4):234-48. (PMID: 26965674); Alcohol Clin Exp Res. 2007 Aug;31(8):1315-24. (PMID: 17550370); J Neurovirol. 2021 Aug;27(4):568-578. (PMID: 34185242); J Clin Exp Neuropsychol. 2017 Nov;39(9):842-853. (PMID: 28122474); Int Psychogeriatr. 2020 Jan;32(1):105-118. (PMID: 31014404); J Int Neuropsychol Soc. 2002 Mar;8(3):410-24. (PMID: 11939699); J Neurol. 2021 May;268(5):1615-1622. (PMID: 31414193); Am J Psychiatry. 2004 Feb;161(2):249-54. (PMID: 14754773); HIV Med. 2021 Oct;22(9):783-790. (PMID: 34291558); J Assoc Nurses AIDS Care. 2019 Jan-Feb;30(1):42-50. (PMID: 30586348); Cureus. 2022 Sep 15;14(9):e29207. (PMID: 36258974); J Neurovirol. 2002 Apr;8(2):136-42. (PMID: 11935465); Neuropsychiatr Dis Treat. 2020 Nov 06;16:2681-2687. (PMID: 33192067); mBio. 2021 Dec 21;12(6):e0278421. (PMID: 34903055); Alcohol Clin Exp Res. 2019 Jan;43(1):147-157. (PMID: 30371953); J Neurovirol. 2014 Oct;20(5):505-13. (PMID: 25201556); J Clin Exp Neuropsychol. 2006 Apr;28(3):383-404. (PMID: 16618627); JAMA Netw Open. 2019 Sep 4;2(9):e1910319. (PMID: 31560382); J Stud Alcohol. 2002 Mar;63(2):179-86. (PMID: 12033694); Cureus. 2022 Dec 18;14(12):e32661. (PMID: 36660505); Cureus. 2022 Jun 13;14(6):e25905. (PMID: 35844323); Neuropsychol Rev. 2019 Sep;29(3):313-327. (PMID: 31440882); J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019); Alzheimers Dement (Amst). 2018 Nov 03;10:773-781. (PMID: 30505927); Neurology. 2010 Dec 7;75(23):2087-96. (PMID: 21135382); AIDS Behav. 2014 Jul;18(7):1302-14. (PMID: 23979498); Alcohol Alcohol. 2019 Jan 9;54(5):477-486. (PMID: 31322648); Drug Alcohol Depend. 2018 Jun 1;187:249-253. (PMID: 29684893); Subst Abuse Treat Prev Policy. 2019 Nov 14;14(1):52. (PMID: 31727086); J Neuroimmune Pharmacol. 2021 Mar;16(1):130-143. (PMID: 31823251); Front Physiol. 2022 Jan 18;12:758230. (PMID: 35115952); Infect Dis Clin Microbiol. 2022 Sep 26;4(3):163-171. (PMID: 38633390); Alcohol Clin Exp Res. 2018 Feb;42(2):403-412. (PMID: 29120490); J Transl Med. 2022 Apr 5;20(1):155. (PMID: 35382817); Alcohol Clin Exp Res. 2016 Dec;40(12):2656-2666. (PMID: 27759882); Alcohol Clin Exp Res. 2019 Apr;43(4):704-709. (PMID: 30748025); Alcohol Clin Exp Res. 2012 Oct;36(10):1738-47. (PMID: 22823125); J Neurovirol. 2005 Apr;11(2):180-9. (PMID: 16036796) |
| Grant Information: | P60 AA009803 United States AA NIAAA NIH HHS; R21 AA030206 United States AA NIAAA NIH HHS; F30 AA030941 United States AA NIAAA NIH HHS; F30AA030941 United States AA NIAAA NIH HHS; T32 AA007577 United States AA NIAAA NIH HHS; R01 AA025996 United States AA NIAAA NIH HHS; T32AA007577 United States AA NIAAA NIH HHS; P60AA009803 United States AA NIAAA NIH HHS |
| Contributed Indexing: | Keywords: HIV‐associated neurocognitive disorders; Montreal cognitive assessment; alcohol misuse; alcohol use disorder; cognitive deficits |
| Entry Date(s): | Date Created: 20240602 Latest Revision: 20260305 |
| Update Code: | 20260305 |
| PubMed Central ID: | PMC12042963 |
| DOI: | 10.1111/acer.15378 |
| PMID: | 38825691 |
| Database: | MEDLINE |
Journal Article